Experiment Overview
flowchart TD
experiments_metabolic_syndrome["Metabolic Syndrome-Parkinsons Disease Axis Clini"]
experiments_metabolic_syndrome["Syndrome-Parkinson"]
experiments_metabolic_syndrome -->|"related to"| experiments_metabolic_syndrome
style experiments_metabolic_syndrome fill:#81c784,stroke:#333,color:#000
experiments_metabolic_syndrome["Trial"]
experiments_metabolic_syndrome -->|"related to"| experiments_metabolic_syndrome
style experiments_metabolic_syndrome fill:#81c784,stroke:#333,color:#000
experiments_metabolic_syndrome["Design"]
experiments_metabolic_syndrome -->|"related to"| experiments_metabolic_syndrome
style experiments_metabolic_syndrome fill:#81c784,stroke:#333,color:#000
experiments_metabolic_syndrome["Experiment"]
experiments_metabolic_syndrome -->|"related to"| experiments_metabolic_syndrome
style experiments_metabolic_syndrome fill:#81c784,stroke:#333,color:#000
style experiments_metabolic_syndrome fill:#4fc3f7,stroke:#333,color:#000
Hypothesis: Metabolic syndrome modulation through [GLP-1 receptor](/entities/glp1-receptor) agonist therapy will improve metabolic parameters, reduce neuroinflammation, and slow disease progression in [Parkinson's disease](/diseases/parkinsons-disease) patients with metabolic dysfunction.
Study Design
...Experiment Overview
Mermaid diagram (expand to render)
Hypothesis: Metabolic syndrome modulation through [GLP-1 receptor](/entities/glp1-receptor) agonist therapy will improve metabolic parameters, reduce neuroinflammation, and slow disease progression in [Parkinson's disease](/diseases/parkinsons-disease) patients with metabolic dysfunction.
Study Design
Population
- Sample Size: 200 participants (100 treatment, 100 placebo)
- Inclusion Criteria:
- Age 50-75 years
- PD diagnosis (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Disease duration 1-8 years
- Evidence of metabolic dysfunction (≥2 of: BMI ≥28, HbA1c 5.7-6.9%, triglycerides >150 mg/dL, HDL <40 mg/dL men/<50 mg/dL women, BP >130/85 mmHg)
- Stable dopaminergic therapy for ≥1 month
- Exclusion Criteria:
- Type 1 or Type 2 diabetes on insulin therapy
- History of pancreatitis
- Current GLP-1 agonist use
- Severe renal or hepatic impairment
- Active cancer
Intervention Arms
Treatment Arm: Liraglutide 1.8 mg daily (titrated over 4 weeks)
- Subcutaneous injection
- Standard diabetes dosing for neuroprotection
2.
Placebo Arm: Matching placebo injection
Duration
- 12-month treatment period
- 6-month follow-up off intervention
Endpoints
Primary Endpoints
Change in MDS-UPDRS Part III (motor score) at 12 months
Change in HbA1c at 12 months (confirm metabolic improvement)Secondary Endpoints
Neuroinflammatory markers (IL-6, TNF-α, CRP, NFL)
Metabolic parameters: BMI, fasting glucose, insulin, HOMA-IR, lipid panel
Motor complications (dyskinesia, motor fluctuations)
Non-motor symptoms:
- PDQ-39
- SCOPA-AUT (autonomic dysfunction)
- MoCA (cognitive function)
- Epworth Sleepiness Scale
5.
Brain imaging:
- DAT-SPECT (dopaminergic transporter binding) at baseline and 12 months
- SWI (iron deposition) in substantia nigra
6.
Biomarkers:
- [Alpha-synuclein](/proteins/alpha-synuclein) seed amplification assay (αSyn-SAA) in CSF](/proteins)
- [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in plasma
Exploratory Endpoints
- Gut [microbiome](/entities/microbiome) composition (16S rRNA sequencing)
- Peripheral blood mononuclear cell (PBMC) mitochondrial function
- [Autophagy](/entities/autophagy) markers in monocytes
Statistical Analysis
Power Calculation
- 80% power to detect 3.5-point difference in MDS-UPDRS III (α=0.05)
- Assuming 20% dropout
- Based on exenatide trial effect size (4.5 points)
Analysis Plan
- Intent-to-treat analysis
- Mixed-effects model for repeated measures
- Stratification by metabolic syndrome severity
- Corrections for multiple comparisons
Risks and Mitigations
| Risk | Mitigation |
|------|------------|
| GI side effects (nausea, vomiting) | Gradual titration, antiemetic as needed |
| Pancreatitis | Exclusion of high-risk patients, lipase monitoring |
| Hypoglycemia | Monitor fasting glucose, exclude intensive insulin users |
| Thyroid C-cell tumors | Exclusion of patients with family history of medullary thyroid carcinoma |
Budget Estimate
- Personnel: $600,000
- Study drug/placebo: $400,000
- Lab assays: $300,000
- Imaging (DAT-SPECT, MRI): $400,000
- Patient compensation: $200,000
- Regulatory/IRB: $100,000
- Contingency (20%): $400,000
- Total: ~$2,400,000
Timeline
| Milestone | Timepoint |
|-----------|-----------|
| IRB submission | Month 0 |
| IND application | Month 2 |
| Recruitment start | Month 6 |
| Last patient enrolled | Month 18 |
| Last patient completed | Month 30 |
| Primary analysis | Month 34 |
Success Criteria
- Primary: Statistically significant improvement in MDS-UPDRS III AND improvement in metabolic parameters
- Secondary: Reduction in neuroinflammatory markers, preservation of DAT binding
- Significance: Would provide evidence for metabolic modulation as disease-modifying therapy in PD
Subgroup Analyses
Patients with vs without metabolic syndrome at baseline
By number of metabolic syndrome components (2 vs 3+)
By baseline HbA1c (prediabetic vs normal)
By PD severity at baselineMechanistic Validation
To validate the hypothesis mechanistically:
Peripheral: Measure mitochondrial function in patient-derived monocytes
CSF: Assess autophagy markers (LC3, p62) and lysosomal function
Imaging: Quantify [brain insulin signaling](/entities/brain-insulin-signaling) via PET (if available)
References
[Athauda et al., Exenatide once weekly versus placebo in Parkinson's disease (2017) (2017)](https://doi.org/10.1016/S1474-4422(17)
[Unknown, GLP-1 receptor agonists and neuroinflammation (2020) (2020)](https://doi.org/10.1016/j.neuropharm.2020.108118)
[Unknown, Metabolic syndrome and Parkinson's disease (2020) (2020)](https://doi.org/10.1002/mds.27982)
[Unknown, Insulin resistance in Parkinson's disease brains (2018) (2018)](https://doi.org/10.1002/mds.104)Pathway Diagram
The following diagram shows the key molecular relationships involving Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)